{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:00:33Z","timestamp":1781632833787,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","award":["2019-05438 and 2023-01943"],"award-info":[{"award-number":["2019-05438 and 2023-01943"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","award":["MH 2018-02688"],"award-info":[{"award-number":["MH 2018-02688"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NIHR Global Health Research Professorship","award":["NIHR300791"],"award-info":[{"award-number":["NIHR300791"]}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["203077\/Z\/16\/Z"],"award-info":[{"award-number":["203077\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["RIA2020EF-3042"],"award-info":[{"award-number":["RIA2020EF-3042"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MRC\/UKRI, UK, African Research Leader","award":["MR\/P020321\/1"],"award-info":[{"award-number":["MR\/P020321\/1"]}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV 064558"],"award-info":[{"award-number":["INV 064558"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Global WHO data indicate that Sub-Saharan African (SSA) countries, such as Kenya, experienced reduced coronavirus disease 2019 (COVID-19) severe-morbidity and mortality burdens relative to their more affluent counterparts in Europe, Asia, and North America.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We analysed peripheral blood mononuclear cells (PBMC) samples collected from Kenya and Sweden before and during COVID-19. Pre-COVID-19 samples were available for 80 adults and 10 infants from Kenya, and 20 adults from Sweden. COVID-19 samples were available for 39 Kenyan adults. The samples were analysed for ex vivo IFN-\u03b3 secretion using an Enzyme-Linked Immunosorbent (ELISpot) assay following in vitro stimulations with overlapping SARS-CoV-2 spike-protein peptides. T-cells expressing IFN-\n                      <jats:italic>\u03b3<\/jats:italic>\n                      , IL-2, TNF-\u03b1, CD154, and CD107a were assessed following similar stimulations, using intracellular cytokine staining (ICS) and multiparameter flow cytometry.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      55.7% of the Kenyan pre-COVID-19 adult samples were classified as responders by ELISPOT responses to spike-protein peptides, compared with 28% of Swedish pre-COVID-19 adult sample (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04). The frequencies for SARS-CoV-2 spike-specific TNF-\u03b1 CD4+, TNF-\u03b1 CD8\u2009+\u2009and IFN-\n                      <jats:italic>\u03b3<\/jats:italic>\n                      CD8\u2009+\u2009T-cell responses, tended to be higher in the Kenyan adults although these differences did not reach statistical significance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pre-COVID-19 T-cell responses could contribute to lower morbidity and mortality associated with SARS-CoV-2 infections in SSA relative to Europe, Asia, and North America.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-026-12582-6","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T09:34:40Z","timestamp":1768642480000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pre-COVID-19 ex vivo cross-reactive IFN-\u03b3 cellular response to SARS-CoV-2 spike overlapping peptides is more prevalent among Kenyan compared to Swedish adults"],"prefix":"10.1186","volume":"26","author":[{"given":"Perpetual","family":"Wanjiku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedict","family":"Orindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jedidah","family":"Mwacharo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Chemweno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry Kibe","family":"Karanja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Kronsteiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Kai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynette Isabella","family":"Ochola-Oyier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Sundling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Dunachie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George M.","family":"Warimwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"F\u00e4rnert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Bejon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis M.","family":"Ndungu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice W.","family":"Nduati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,17]]},"reference":[{"issue":"13","key":"12582_CR1","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/jama.2020.2648","volume":"323","author":"Z Wu","year":"2020","unstructured":"Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239\u201342.","journal-title":"JAMA"},{"issue":"8","key":"12582_CR2","doi-asserted-by":"publisher","first-page":"e1099","DOI":"10.1016\/S2214-109X(22)00233-9","volume":"10","author":"JW Cabore","year":"2022","unstructured":"Cabore JW, Karamagi HC, Kipruto HK, Mungatu JK, Asamani JA, Droti B, et al. COVID-19 in the 47 countries of the WHO African region: a modelling analysis of past trends and future patterns. Lancet Glob Health. 2022;10(8):e1099\u2013114.","journal-title":"Lancet Glob Health"},{"key":"12582_CR3","doi-asserted-by":"crossref","unstructured":"Osayomi T, Adeleke R, Akpoterai LE, Fatayo OC, Ayanda JT, Moyin-Jesu J et al. A geographical analysis of the african COVID-19 Paradox: Putting the poverty-as-a-vaccine hypothesis to the test. Earth Syst Environ. 2021 Sept 1;5(3):799\u2013810.","DOI":"10.1007\/s41748-021-00234-5"},{"key":"12582_CR4","doi-asserted-by":"crossref","unstructured":"Ghosh D, Bernstein JA, Mersha TB. COVID-19 pandemic: the African paradox. J Glob Health 10(2):020348.","DOI":"10.7189\/jogh.10.020348"},{"issue":"6524","key":"12582_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1126\/science.abf8832","volume":"371","author":"JM Maeda","year":"2021","unstructured":"Maeda JM, Nkengasong JN. The puzzle of the COVID-19 pandemic in Africa. Science. 2021;371(6524):27\u20138.","journal-title":"Science"},{"issue":"16","key":"12582_CR6","doi-asserted-by":"publisher","first-page":"8638","DOI":"10.3390\/ijerph18168638","volume":"18","author":"RG Wamai","year":"2021","unstructured":"Wamai RG, Hirsch JL, Van Damme W, Alnwick D, Bailey RC, Hodgins S, et al. What could explain the lower COVID-19 burden in Africa despite considerable circulation of the SARS-CoV-2 virus? Int J Environ Res Public Health. 2021;18(16):8638.","journal-title":"Int J Environ Res Public Health"},{"key":"12582_CR7","doi-asserted-by":"crossref","unstructured":"Escobar LE, Molina-Cruz A, Barillas-Mury C. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). Proc Natl Acad Sci U S 2020 July 28;117(30):17720\u20136.","DOI":"10.1073\/pnas.2008410117"},{"key":"12582_CR8","doi-asserted-by":"publisher","first-page":"632478","DOI":"10.3389\/fimmu.2021.632478","volume":"12","author":"M Gonzalez-Perez","year":"2021","unstructured":"Gonzalez-Perez M, Sanchez-Tarjuelo R, Shor B, Nistal-Villan E, Ochando J. The BCG vaccine for COVID-19: first verdict and future directions. Front Immunol. 2021;12:632478.","journal-title":"Front Immunol"},{"issue":"8","key":"12582_CR9","doi-asserted-by":"publisher","first-page":"114533","DOI":"10.1016\/j.celrep.2024.114533","volume":"43","author":"K Tapela","year":"2024","unstructured":"Tapela K, Prah DA, Tetteh B, Nuokpem F, Dosoo D, Coker A, et al. Cellular immune response to SARS-CoV-2 and clinical presentation in individuals exposed to endemic malaria. Cell Rep. 2024;43(8):114533.","journal-title":"Cell Rep"},{"issue":"4","key":"12582_CR10","doi-asserted-by":"publisher","first-page":"e215","DOI":"10.1016\/S2666-5247(22)00295-6","volume":"4","author":"J Ashworth","year":"2023","unstructured":"Ashworth J, Mathie D, Scott F, Mahendran Y, Woolhouse M, Stoevesandt O, et al. Peptide microarray IgM and IgG screening of pre-SARS-CoV-2 human serum samples from Zimbabwe for reactivity with peptides from all seven human coronaviruses: a cross-sectional study. Lancet Microbe. 2023;4(4):e215\u201327.","journal-title":"Lancet Microbe"},{"issue":"7833","key":"12582_CR11","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2598-9","volume":"587","author":"J Braun","year":"2020","unstructured":"Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature. 2020;587(7833):270\u20134.","journal-title":"Nature"},{"issue":"7821","key":"12582_CR12","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41586-020-2550-z","volume":"584","author":"N Le Bert","year":"2020","unstructured":"Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020;584(7821):457\u201362.","journal-title":"Nature"},{"key":"12582_CR13","doi-asserted-by":"crossref","unstructured":"Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 2020 June 25;181(7):1489\u2013e150115.","DOI":"10.1016\/j.cell.2020.05.015"},{"key":"12582_CR14","doi-asserted-by":"crossref","unstructured":"Weiskopf D, Schmitz KS, Raadsen MP, Grifoni A, Okba NMA, Endeman H et al. Phenotype and kinetics of SARS-CoV-2\u2013specific T cells in COVID-19 patients with acute respiratory distress syndrome. Science Immunology. 2020 June 26;5(48):eabd2071.","DOI":"10.1126\/sciimmunol.abd2071"},{"issue":"6512","key":"12582_CR15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1126\/science.abd3871","volume":"370","author":"J Mateus","year":"2020","unstructured":"Mateus J, Grifoni A, Tarke A, Sidney J, Ramirez SI, Dan JM, et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science. 2020;370(6512):89\u201394.","journal-title":"Science"},{"issue":"4","key":"12582_CR16","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","volume":"184","author":"A Sette","year":"2021","unstructured":"Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184(4):861\u201380.","journal-title":"Cell"},{"issue":"6564","key":"12582_CR17","doi-asserted-by":"publisher","first-page":"eabh1823","DOI":"10.1126\/science.abh1823","volume":"374","author":"L Loyal","year":"2021","unstructured":"Loyal L, Braun J, Henze L, Kruse B, Dingeldey M, Reimer U, et al. Cross-reactive CD4\u2009+\u2009T cells enhance SARS-CoV-2 immune responses upon infection and vaccination. Science. 2021;374(6564):eabh1823.","journal-title":"Science"},{"key":"12582_CR18","doi-asserted-by":"crossref","unstructured":"Poston D, Weisblum Y, Wise H, Templeton K, Jenks S, Hatziioannou T et al. Absence of severe acute respiratory syndrome coronavirus 2 Neutralizing activity in prepandemic sera from individuals with recent seasonal coronavirus infection. Clin Infect Dis. 2021 Sept 7;73(5):e1208\u201311.","DOI":"10.1093\/cid\/ciaa1803"},{"issue":"1","key":"12582_CR19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.it.2020.11.002","volume":"42","author":"P de Candia","year":"2021","unstructured":"de Candia P, Prattichizzo F, Garavelli S, Matarese GT, Cells. Warriors of SARS-CoV-2 infection. Trends Immunol. 2021;42(1):18\u201330.","journal-title":"Trends Immunol"},{"issue":"1","key":"12582_CR20","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","volume":"183","author":"T Sekine","year":"2020","unstructured":"Sekine T, Perez-Potti A, Rivera-Ballesteros O, Str\u00e5lin K, Gorin JB, Olsson A, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell. 2020;183(1):158\u2013e16814.","journal-title":"Cell"},{"issue":"8","key":"12582_CR21","doi-asserted-by":"publisher","first-page":"e0001566","DOI":"10.1371\/journal.pgph.0001566","volume":"3","author":"A Namuniina","year":"2023","unstructured":"Namuniina A, Muyanja ES, Biribawa VM, Okech BA, Ssemaganda A, Price MA, et al. Proportion of Ugandans with pre-pandemic SARS-CoV-2 cross-reactive CD4\u2009+\u2009and CD8\u2009+\u2009T-cell responses: A pilot study. PLOS Global Public Health. 2023;3(8):e0001566.","journal-title":"PLOS Global Public Health"},{"key":"12582_CR22","doi-asserted-by":"publisher","unstructured":"Nantambi H, Sembera J, Ankunda V, Ssali I, Kalyebi AW, Oluka GK et al. Pre-pandemic SARS-CoV-2-specific IFN-\u03b3 and antibody responses were low in Ugandan samples and significantly reduced in HIV-positive specimens. Front Immunol [Internet]. 2023 Apr 19 [cited 2024 Sept 23];14. Available from: https:\/\/www.frontiersin.org\/journals\/immunology\/articles\/https:\/\/doi.org\/10.3389\/fimmu.2023.1148877\/full","DOI":"10.3389\/fimmu.2023.1148877\/full"},{"key":"12582_CR23","doi-asserted-by":"publisher","unstructured":"Herrera BB, Chaplin B, MBoup S, Abdullahi A, He M, Fisher SM et al. West African pre-pandemic cross-reactive antibody and cellular responses against SARS-CoV-2 [Internet]. medRxiv; 2024 [cited 2024 Sept 23]. p. 2024.05.21.24307417. Available from: https:\/\/www.medrxiv.org\/content\/https:\/\/doi.org\/10.1101\/2024.05.21.24307417v1","DOI":"10.1101\/2024.05.21.24307417v1"},{"key":"12582_CR24","doi-asserted-by":"crossref","unstructured":"Nunes MC, Johnson MJ, Kwatra G, Weinberg A, Madhi SA. T-cell responses to SARS-CoV-2 in unexposed South African women. Gates Open Res 2022 July 13;5:150.","DOI":"10.12688\/gatesopenres.13373.2"},{"issue":"2","key":"12582_CR25","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-020-01194-5","volume":"27","author":"KJ Ewer","year":"2021","unstructured":"Ewer KJ, Barrett JR, Belij-Rammerstorfer S, Sharpe H, Makinson R, Morter R, et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1\/2 clinical trial. Nat Med. 2021;27(2):270\u20138.","journal-title":"Nat Med"},{"issue":"1","key":"12582_CR26","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1038\/s41467-021-21856-3","volume":"12","author":"A Ogbe","year":"2021","unstructured":"Ogbe A, Kronsteiner B, Skelly DT, Pace M, Brown A, Adland E, et al. T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. Nat Commun. 2021;12(1):2055.","journal-title":"Nat Commun"},{"key":"12582_CR27","doi-asserted-by":"crossref","unstructured":"Wanjiku P, Orindi B, Kimotho J, Sayed S, Shah R, Saleh M et al. Induction of an early IFN-\u03b3 cellular response and high plasma levels of SDF-1\u03b1 are inversely associated with COVID-19 severity and residence in rural areas in Kenyan patients. PLOS One. 2025 Sept 11;20(9):e0316967.","DOI":"10.1371\/journal.pone.0316967"},{"key":"12582_CR28","unstructured":"Graph pad prism programming team. Graph pad Prism, Boston, Massachusetts, USA. 2023 [cited 2024 Apr 11]. Prism - GraphPad. Available from: https:\/\/www.graphpad.com\/features"},{"issue":"10","key":"12582_CR29","doi-asserted-by":"publisher","first-page":"e617","DOI":"10.1002\/iid3.617","volume":"10","author":"J Villemonteix","year":"2022","unstructured":"Villemonteix J, Cohen L, Guihot A, Gu\u00e9rin V, Moulin C, Caseris M, et al. Comparison between enzyme-linked immunospot assay and intracellular cytokine flow cytometry assays for the evaluation of T cell response to SARS-CoV-2 after symptomatic COVID-19. Immun Inflamm Dis. 2022;10(10):e617.","journal-title":"Immun Inflamm Dis"},{"key":"12582_CR30","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ijid.2020.10.104","volume":"102","author":"FY Tso","year":"2021","unstructured":"Tso FY, Lidenge SJ, Pe\u00f1a PB, Clegg AA, Ngowi JR, Mwaiselage J, et al. High prevalence of pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa. Int J Infect Dis. 2021;102:577\u201383.","journal-title":"Int J Infect Dis"},{"key":"12582_CR31","doi-asserted-by":"publisher","first-page":"1343716","DOI":"10.3389\/fimmu.2024.1343716","volume":"15","author":"PG Coulon","year":"2024","unstructured":"Coulon PG, Prakash S, Dhanushkodi NR, Srivastava R, Zayou L, Tifrea DF, et al. High frequencies of alpha common cold coronavirus\/SARS-CoV-2 cross-reactive functional CD4\u2009+\u2009and CD8\u2009+\u2009memory T cells are associated with protection from symptomatic and fatal SARS-CoV-2 infections in unvaccinated COVID-19 patients. Front Immunol. 2024;15:1343716.","journal-title":"Front Immunol"},{"key":"12582_CR32","doi-asserted-by":"crossref","unstructured":"Sagar M, Reifler K, Rossi M, Miller NS, Sinha P, White LF et al. Recent endemic coronavirus infection is associated with less-severe COVID-19. J Clin Invest [Internet]. 2021 Jan 4 [cited 2024 Oct 30];131(1). Available from: https:\/\/www.jci.org\/articles\/view\/143380","DOI":"10.1172\/JCI143380"},{"issue":"2","key":"12582_CR33","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","volume":"23","author":"P Moss","year":"2022","unstructured":"Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol. 2022;23(2):186\u201393.","journal-title":"Nat Immunol"},{"key":"12582_CR34","doi-asserted-by":"publisher","unstructured":"Wyllie D, Jones HE, Mulchandani R, Trickey A, Taylor-Phillips S, Brooks T et al. SARS-CoV-2 responsive T cell numbers and anti-Spike IgG levels are both associated with protection from COVID-19: a prospective cohort study in keyworkers [Internet]. medRxiv; 2021 [cited 2024 Sept 20]. p. 2020.11.02.20222778. Available from: https:\/\/www.medrxiv.org\/content\/https:\/\/doi.org\/10.1101\/2020.11.02.20222778v2","DOI":"10.1101\/2020.11.02.20222778v2"},{"issue":"1","key":"12582_CR35","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41467-021-27674-x","volume":"13","author":"R Kundu","year":"2022","unstructured":"Kundu R, Narean JS, Wang L, Fenn J, Pillay T, Fernandez ND, et al. Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts. Nat Commun. 2022;13(1):80.","journal-title":"Nat Commun"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-12582-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12582-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12582-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:47:17Z","timestamp":1781632037000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-12582-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,17]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12582"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-12582-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,17]]},"assertion":[{"value":"19 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the ethical principles for medical research involving humans, including research on identifiable human material, as declared in Helsinki in 1964. We received ethical approval from the Kenya Medical Research Institute\u2019s (KEMRI) Scientific and Ethics Review Unit (SERU) under protocols SERU 3149, 4081 and 4085. Ethical approval for the collection of the Swedish samples was obtained from the regional Ethics Committee in Stockholm, Sweden under protocols 2006\/893\u2009\u2212\u200931\/4 and 2019\u201303436. Each participant, or their parent or legal guardian, provided informed consent for their respective samples to be used for both the contemporaneous and future research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"174"}}